reports
- Patrik Ling
Getinge (Buy, TP: SEK240.00) - Uncertainty regarding FDA issues
Getinge yesterday hosted a meeting to discuss its new long-term financial targets, where it also commented on the recent FDA communication to healthcare facilities in the US advising users to transition away from Getinge’s equipment in cardiopulmonary and cardiac assist. However, the company has limited visibility on the size of the financial impact. We reiterate our BUY, but have lowered our target price to SEK240 (255).
- Patrik Ling
PhotoCure (Buy, TP: NOK87.00) - Solid start to the year
A 3% outperformance on Q1 sales versus our estimate and consensus together with lower operating expenses helped EBITDA beat our forecast by 193% (but cNOK5m in absolute terms). Management reiterated its guidance for 6–9% organic product sales growth in 2024 and positive EBITDA (excluding business development costs). We reiterate our BUY and NOK87 target price.
- ABGSC Healthcare Research
- Sten Gustafsson
- ABGSC Healthcare Research
- Sten Gustafsson
- Patrik Ling
Egetis Therapeutics - Initiation of coverage - A rare opportunity
Egetis Therapeutics is a biotech company with a focus on rare diseases. Lead compound Emcitate (targeting MCT8 deficiency) is under registration in Europe, and a pivotal trial is ongoing in the US. Despite Emcitate’s advanced stage of development, the stock has been rangebound of late: in our view this offers an attractive entry point. We initiate coverage with a BUY and SEK18 target price.
- Geir Hiller Holom
Nykode Therapeutics (Buy, TP: NOK31.00) - Q1 report and Merck collabor...
While the Q1 report contained no large surprises (the expected upcoming events near-term seem on track), the company also announced a collaboration with MSD (Merck) to evaluate VB10.16 in combination with KEYTRUDA (pembrolizumab) in patients with HPV16-associated high-risk locally advanced cervical cancer. Management is due to present the results at a live-streamed webcast at 16:00 CET today.
- ABGSC Healthcare Research
- Alexander Krämer
Nykode Therapeutics Announces Clinical Collaboration with MSD to Evalu...
Nykode Therapeutics Announces Clinical Collaboration with MSD to Evaluate VB10.16 in Combination with KEYTRUDA® (pembrolizumab) in Patients with HPV16-Positive High-Risk Locally Advanced Cervical Cancer OSLO, Norway, May 14, 2024 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced that it has expanded its collaboration with MSD (Merck & Co., Inc., Rahway, NJ, USA) to include a clinical trial collaboration and supply agreement for a phase 2 trial evaluating N...
Nykode Therapeutics - Quarterly report Q1 2024
Nykode Therapeutics - Quarterly report Q1 2024 OSLO, Norway, May 14, 2024 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced its unaudited financial results for the first quarter of 2024. The financial report can be accessed in the Investors section of the Company’s website: . The Company will host a webcast presentation at 4 p.m. CET / 10 a.m. ET. A live and archived webcast of the presentation can be accessed in the Investors section of the ...
- Geir Hiller Holom
Circio Holding (No_rec, TP: NOK) - Recommendation and target price wit...
We continue to like Circio’s focus on the circRNA programme and believe it will be able to secure a partnering deal in 2025. However, the funding situation is unclear. It recently announced an intention to raise cNOK50m–60m in Q2. As we have limited input on the terms of the upcoming capital raise and Atlas Capital Markets’ (the counterparty of the convertible bond facility announced in February 2023) degree of participation and conditions, we have withdrawn our target price and recommendation.
- Patrik Ling
PhotoCure (Buy, TP: NOK87.00) - Focusing on underlying business
We have made limited estimate changes ahead of the Q1 results (due at 08:00 CET on 15 May), and believe Photocure is moving forward in areas within its control. YOY comparables are affected by Q1 2023 being the last quarter with flex sales in the US. Its partner, Asieris, has filed for marketing approval of Cevira in China; if accepted for review, we believe Photocure would be in line for another milestone payment in Q2. We reiterate our BUY and NOK87 target price.
- Geir Hiller Holom
Ultimovacs (Sell, TP: NOK4.00) - Slower recruitment, FOCUS in focus
Total operating expenses were NOK28.6m, and cash and cash equivalents were NOK220m at end-Q1 (NOK266.6m at end-Q4 2023). The company recently announced initiatives to extend the financial runway to Q4 2025. While data from the fully recruited FOCUS trial is expected in Q3, the number of new recruited patients in the DOVACC and LUNGVAC trials was lower in Q1 versus Q4 2023. We reiterate our SELL and NOK4 target price.
- Maria Vara
BICO: profitability impacted by mixed sales in Q1 2024; CMD in Septemb...
BICO has reported Q1 2024 net sales amounting to SEK 510.3m (+2% vs. css) implying 4.4% YoY growth and organic growth of 4.7% (-1.1%). The Biosciences segment outperformed with net sales showing 36.3% organic growth to SEK 310m (SEK 230m), while Bioprinting and Bioautomation fell short of expectati
- ABGSC Healthcare Research
- Alexander Krämer
Ultimovacs ASA Reports First Quarter 2024 Financial Results and Provid...
Ultimovacs ASA Reports First Quarter 2024 Financial Results and Provides General Business Update Ultimovacs remains committed to continuing the clinical development strategy and exploring multiple pathways for UV1.The negative INITIUM results have had important consequences for the Company. Implemented cash preservation initiatives extends the anticipated financial runway to the fourth quarter of 2025, beyond the anticipated topline readout of the FOCUS and DOVACC trials. The UV1 vaccine was granted Fast Track designation from the U.S. Food and Drug Administration (FDA) and Orphan Drug desi...
PCI Biotech Holding ASA - Notice of Annual General Meeting 2024
PCI Biotech Holding ASA - Notice of Annual General Meeting 2024 Oslo, Norway 3 May 2024 - The annual general meeting of PCI Biotech Holding ASA will be held at the company’s office at Oslo Cancer Cluster Innovation Park, on 24 May 2024 at 10:00am (CEST). The notice and proposed resolutions to the annual general meeting are attached. The notice, including all appendices, will be made available at PCI Biotech's corporate website . For further information, please contact:Ronny Skuggedal, CEO/CFO, E-mail: Office: Mobile: This information is subject to the disclosure requirements...
- ABGSC Healthcare Research
- Alexander Krämer
- Oscar Haffen Lamm
Egetis reports Q1, on track with US trial
Egetis reported Q1 2024 results with an operating loss of SEK (68.6m) and a cash position of SEK 251.7m. In the pipeline, the most important update has been to the status of the critical US phase 3 trial, where the company reported that 13/16 patients have been recruited, whereof 6 patients have co
Ultimovacs ASA: Invitation to first quarter 2024 results webcast prese...
Ultimovacs ASA: Invitation to first quarter 2024 results webcast presentation Oslo, April 30, 2024: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, invites to a webcast presentation of its first quarter 2024 results on Tuesday, May 7, 2024. The presentation can be followed as a live webcast accessed through a link on at 14:00 CET on Tuesday, May 7, 2024, and is scheduled to conclude at 14:55 CET. The webcast presentation will be available on the Ultimovacs website, and it will be possible to post questions duri...
PCI Biotech Holding ASA - Annual Report 2023
PCI Biotech Holding ASA - Annual Report 2023 Oslo, Norway, April 26, 2024.The Board of Directors of PCI Biotech Holding ASA has approved the Annual Report 2023. Please find the report attached, as well as the report according to the European Single Electronic Format (ESEF). The Annual Report 2023 is also available on the company’s website For further information, please contact: PCI Biotech Holding ASA, Ullernchausséen 64, N-0379 Oslo Ronny Skuggedal, CEO, , Mobile: 757This information is subject to the disclosure requirements pursuant to section 5...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.